ArticleJournal of cardiovascular translational research2026
ChemoCardioNet: An Explainable Multimodal Transformer for Early Prediction of Chemotherapy-Induced Cardiotoxicity.
Article in Journal of cardiovascular translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemotherapy-induced cardiotoxicity (CIC) remains a major cause of morbidity and mortality among cancer survivors, and conventional monitoring often fails to detect early subclinical cardiac injury. We propose ChemoCardioNet, an explainable multimodal deep learning framework that predicts cardiotoxicity risk before clinical manifestation by integrating electrocardiograms (ECG), echocardiography, clinical variables, and serum biomarkers. The architecture combines modality-specific encoders, including 1D convolutional transformers for ECG sequences, CNN-ViT hybrid blocks for echocardiographic frames, and multilayer perceptrons for clinical and biomarker features. A cross-attention fusion transformer aligns latent representations across modalities and captures temporal evolution across chemotherapy cycles. The model outputs a probabilistic cardiotoxicity risk score with feature-level explainability using SHAP analysis. In a cohort of 1,200 patients, ChemoCardioNet achieved an AUC of 0.92, outperforming single-modality and traditional machine learning approaches by 8-12%. The model predicted cardiotoxicity approximately two cycles before detectable echocardiographic dysfunction, supporting earlier risk identification and improved cardio-oncology monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.